Skip to content
Open access

Peptide-Functionalized Gold Nanoparticles Targeting PD-L1: Design via a Molecular Dynamic Driven Approach and Further Experimental Validation.

Aug 2026 · ACS Applied Bio Materials · Vol 9 16, pp. 7637-7649 · 0 citations · 76 references
Medicine

TL;DR

Design and development of theranostic gold nanostructures functionalized with PD-L1-targeting peptides (PTP, sPTP, and rPTP) whose sequences were identified combining structural analysis of the PD-1/PD-L1 interaction interface and molecular dynamics simulations are reported.

Abstract

The development of theranostic tools for the early detection and localization of tumors represents a major challenge in oncology. Among emerging strategies, the targeting of Programmed Death Ligand-1 (PD-L1), a key immune checkpoint protein overexpressed in many tumor types, has gained significant attention. In this work, we report design and development of theranostic gold nanostructures functionalized with PD-L1-targeting peptides (PTP, sPTP, and rPTP) whose sequences were identified combining structural analysis of the PD-1/PD-L1 interaction interface and molecular dynamics simulations. This is because the design of functional nanostructures for protein targeting requires a precise understanding of how molecular recognition is affected by ligand organization at interfaces; therefore, peptide design was guided not only by the selection of key residues involved in binding but also by the evaluation of peptide assemblies to explicitly account for the collective effects governing target recognition. Indeed, beyond conventional evaluation of protein/single-peptide interaction, peptide clusters and surface-anchored monolayers were investigated to consider features like peptide assembly, organization, and reduced conformational freedom in the nanostructure/PD-L1 interaction. Results indicate that peptide sequence and orientation critically determine monolayer organization and accessibility of the PD-L1 binding motif. The computational predictions were experimentally validated by synthesizing peptide-functionalized gold nanostructures and evaluating their targeting performance against MDA-MB-231 breast cancer cells over-expressing PD-L1, using the surface-enhanced Raman scattering technique: NS functionalized with PTPs achieved the targeting of approximately 85% of MDA-MB-231 cells at 100 pM nanostructure concentration, compared to 23% for those functionalized with rPTP, demonstrating a nearly four-fold difference attributable exclusively to peptide orientation on the nanostructure surface. The specific system investigated in this work establishes a computational framework for the rational design of peptide-functionalized nanostructures, providing insights into the collective behavior of peptide monolayers and offering a smart methodology that, while demonstrated here for targeting PD-L1, is in principle applicable to other protein targets.

Read PDF

Similar papers

Open access Jul 2026

Dual-targeting CD73/PD-L1 bifunctional inhibitor: a promising cancer immunotherapy strategy

CP-1 exhibits balanced, dual-nanomolar inhibitory activity against PD-L1 and CD73 and displays potent immunomodulatory effects at the cellular level and serves as a promising lead candidate for developing novel bifunctional agents to advance tumor immunotherapy.

Jing-Jing Du, Sen Wu, Shiyun Cheng et al. · 0 citations
Jul 2026

Fragment-based diffusion modeling and molecular dynamics simulation validation for the discovery of PD-L1 small-molecule inhibitors.

Fragment-based diffusion modeling is an efficient and interpretable strategy for the discovery of computationally prioritized PD-L1 small-molecule candidate inhibitors and offers a promising framework for tackling challenging targets in cancer immunotherapy.

Jun Liu, Yuxing Yi, Xiaoyan Wu et al. · 0 citations
Review 2026

Recent strategies and approaches for the development of molecularly targeted nanomedicine.

This chapter highlights the role of targeting ligands, stimuli-responsive systems, and tumor microenvironment-specific strategies in enhancing therapeutic efficacy while minimizing adverse effects, emphasizing the potential of molecularly targeted nanomedicine to advance precision therapy and improve clinical outcomes.

Aman Kumar, Md Hidul Islam, Pranav Dhingra et al. · 0 citations
Jul 2026

Target-Specific TMD Nanosheet Antagonists for Treatment of Breast Cancer

A target protein-selective transition metal dichalcogenide (TMD) nanosheet antagonist that exhibits strong binding affinity and intense Raman scattering signals for the treatment of breast cancer is designed and effectively suppressed tumor growth in vitro and in vivo, thereby enhancing the therapeutic efficacy in mice...

Yujin Choi, Sin Lee, Yoonhee So et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.